In light of the increasing global demand for HMOs, Kyowa Hakko Bio is eyeing opportunities within the Chinese and Thai markets, despite a hazy regulatory environment. Moreover, the company is investing in a new Thai facility to expand its production capacity. Kentaro Yanashima, Research & Business Development for Kyowa Hakko Bio, tells NutritionInsight all about the promising potential of HMO’s for both infant and adult nutrition and the company’s expansion plans.
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement















